Santos BRMD, Santos CHMD, Santos VRMD, Torrez CYG, Palomares-Junior D. PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN'S DISEASE.
ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA 2020;
33:e1522. [PMID:
33237166 PMCID:
PMC7682148 DOI:
10.1590/0102-672020200002e1522]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/02/2019] [Accepted: 04/05/2020] [Indexed: 11/21/2022]
Abstract
Background:
Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease
(CD), so identifying factors related to loss of response is of great
importance in clinical practice.
Aim:
Identify potential factors related to loss of response to anti-TNF agents in
Crohn’s disease patients.
Methods:
This is a prospective study of CD patients attending a specialized outpatient
clinic using a specific form, including patients with more than one year of
follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The
information obtained was tabulated and analyzed to identify possible reasons
for the loss of response to anti-TNF agents; results were submitted to
statistical analysis by chi-square teste considering significant p<0.05.
Results:
Sixty-four patients were included, most of them females (56.3%), predominant
age group between 26 and 55 years, of whom 25 required optimization, 23
remained in remission with the usual dose and interval, and 16 required
switch; most of those who needed switch had hematological problems such as
anemia and/or had already undergone surgical treatment for CD.
Conclusions:
Anemia and prior CD surgery have been linked to loss of anti-TNF
response.
Collapse